Holen Sie sich die Stockscreener-App
26.33
0.15%
-0.04
Handel nachbörslich:
26.70
0.37
+1.41%
Schlusskurs vom Vortag:
$26.37
Offen:
$26.79
24-Stunden-Volumen:
171.15K
Relative Volume:
12.63
Marktkapitalisierung:
$1.59B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$25.56
$27.60
1-Wochen-Bereich:
$21.98
$27.60
52-Wochen-Spanne:
$21.98
$27.60
Damora Therapeutics Inc Stock (DMRA) Company Profile
Firmenname
Damora Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare DMRA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
26.33 | 1.59B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Damora Therapeutics Inc Aktie (DMRA) Neueste Nachrichten
Taxes of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Statistics – NASDAQ:DMRA - TradingView
Total assets of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Galecto Changes Name to Damora Therapeutics, Advances mutCALR Antibody Pipeline for Blood Disorders and Secures $535M Funding 1 - Minichart
Galecto Rebrands as Damora Therapeutics with New Ticker - TipRanks
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders - Bitget
Galecto (GLTO) Rebrands to Damora Therapeutics, Plans Nasdaq Lis - GuruFocus
Galecto rebrands as Damora Therapeutics, begins Nasdaq trading - Investing.com
Damora Therapeutics holds $535M cash to target rare blood cancers - Stock Titan
Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Galecto announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Biotech brings in cancer drug veterans as it readies new antibody trial - Stock Titan
Mintz Advises Galecto, Inc. in its acquisition of Damora Therapeutics, Inc. and its concurrent $285 million private placement - Mintz
US: Galecto acquires Damora Tx and raises US$285m from Series C - Investors in Healthcare
Galecto Stock Surges Premarket After Damora Acquisition — Retail Bulls Predict Another Massive Rally - Stocktwits
A Week Is A Long Time In Biotech, Just Ask Galecto - Citeline News & Insights
Galecto, Inc. (GLTO) Stock: Rockets After $284.9M Funding Boost and Strategic Damora Acquisition - parameter.io
Galecto Reports First Quarter 2025 Operating and Financial Results - marketscreener.com
GLTO Stock Price, News & Analysis - Stock Titan
Galecto to Participate in Upcoming Investor Conferences - marketscreener.com
Galecto Reports Third Quarter 2024 Financial Results - marketscreener.com
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - marketscreener.com
Galecto Announces Reverse Stock Split - marketscreener.com
Galecto to Present at Investor Conferences in September - marketscreener.com
Galecto Set to Join Russell Microcap® Index - marketscreener.com
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference - marketscreener.com
Galecto to Participate in SVB Securities Global Biopharma Conference - marketscreener.com
GALECTO, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - marketscreener.com
Galecto, Inc. Appoints Dr. Jayson Dallas to Board of Directors - marketscreener.com
DMRA Stock Price and Chart — NASDAQ:DMRA - TradingView
Galecto Biotech AB Appoints Richard Marshall as Chief Medical Officer - marketscreener.com
Finanzdaten der Damora Therapeutics Inc-Aktie (DMRA)
Es liegen keine Finanzdaten für Damora Therapeutics Inc (DMRA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
Kapitalisierung:
|
Volumen (24h):